LONDON: Genzyme, the world's third-largest biotech company, has appointed HCC De Facto to handle its European corporate communications. US-based Genzyme has taken on the firm to assist on areas such as regulatory affairs and marketing.Genzyme is at the forefront of research into transgenic transplants - the genetic modification of animals so they can be used to treat human ailments. HCC, which last year recorded fee income from healthcare work of just under ?500,000 ($714,000), got much coverage when it applied for permission to inject cells from transgenic pigs into the brains of Parkinson's patients.
HCC MD Richard Cripps will head the account, which is serviced from its offices in London and Munich, Germany.
Genzyme has three divisions: Genzyme Biosurgery deals with surgical products; Genzyme General focuses on therapeutic and diagnostic products for genetic disorders and chronic debilitating diseases; while Genzyme Molecular Oncology seeks vaccines and treatments for cancer through gene therapy.
Current campaigns include promoting the value of "genetic counseling" (screening) in ensuring a healthy pregnancy.